This study investigated the effects of vitamin D supplementation on Generalized Anxiety Disorder (GAD) clinical symptoms and neurochemical biomarkers including serotonin, neopterin and kynurenine. Thirty male and female patients diagnosed with GAD and had vitamin D deficiency were recruited from the psychiatric clinic at King Abdulaziz University Hospital and divided into two groups; one group of patients (n = 15) received standard of care (SOC) plus 50,000 IU vitamin D (once/week) for 3 months, while the other group (n = 15) received SOC alone. Biochemical parameters including serum vitamin D, serotonin, neopterin and kynurenine were measured for all patients enrolled in the trial. In addition, the Generalized Anxiety Disorder 7-item (GAD-7) scale was used to measure the severity of GAD symptoms in both vitamin D treated- and untreated-patients. Significant improvements in GAD scores were observed in the vitamin D-treated group compared to the group that did not receive vitamin D. In addition, serum serotonin concentrations were significantly increased while serum neopterin were significantly decreased in vitamin D-treated vs. untreated patients. In contrast, no significant differences were found in serum kynurenine concentrations at the end of the study period between the two groups. No changes either in GAD-7 scores or in any of the biochemical measurements were observed in the group that received only SOC after 3 months. Vitamin D supplementation was effective in ameliorating the severity of GAD symptoms by increasing serotonin concentrations and decreasing the levels of the inflammatory biomarker neopterin in GAD patients.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Al-Daghri NM (2018) Vitamin D in Saudi Arabia: prevalence, distribution and disease associations. J Steroid Biochem Mol Biol 175:102–107
Al-Modayfer O, Alatiq Y (2015) A pilot study on the prevalence of psychiatric disorders among Saudi children and adolescents: a sample from a selected community in Riyadh city. Arab J Psychiatry 26(2):184–192
Berger M, Gray JA, Roth BL (2009) The expanded biology of serotonin. Ann Rev Med 60:355–366
Bicikova M, Duskova M, Vitku J, Kalvachova B, Ripova D, Mohr P (2015) Starka L (2015) vitamin D in anxiety and affective disorders. Physiol Res 64(suppl 2):S101–S103
Boldrini P, Fusco A, Nicoletti F, Badiani A, Saso L (2018) Potential use of modulators of oxidative stress as add-on therapy in patients with anxiety disorders. Curr Drug Targets 19(6):636–650
Bouayed J, Rammal H, Soulimani R (2009) Oxidative stress and anxiety: relationship and cellular pathways. Oxidative Med Cell Longev 2(2):63–67
Bouayed J, Hoffmann L, Bohn T (2011) Total phenolics, flavonoids, anthocyanins and antioxidant activity following simulated gastro-intestinal digestion and dialysis of apple varieties: bioaccessibility and potential uptake. Food Chem 128(1):14–21
DeLuca HF (2004) Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 80(6):1689S–1696S
DeLuca GC, Kimball SM, Kolasinski J, Ramagopalan SV, Ebers GC (2013) Review: the role of vitamin D in nervous system health and disease. Neuropathol Appl Neurobiol 39(5):458–484
Eison MS (1990) Serotonin: a common neurobiologic substrate in anxiety and depression. J Clin Psychopharmacol 10(3 Suppl):26S–30S
Fedotova J, Zarembo D, Dragasek J, Caprnda M, Kruzliak P, Dudnichenko T (2017) Modulating effects of cholecalciferol treatment on estrogen deficiency-induced anxiety-like behavior of adult female rats. Folia Med 59(2):139–158
Gautam M, Agrawal M, Gautam M, Sharma P, Gautam AS, Gautam S (2012) Role of antioxidants in generalised anxiety disorder and depression. Indian J Psychiatry 54(3):244–247
Grant BF, Hasin DS, Stinson FS, Dawson DA, June Ruan W, Goldstein RB, Smith SM, Saha TD, Huang B (2005) Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on alcohol and related conditions. Psychol Med 35(12):1747–1759
Griebel G (1995) 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol Ther 65(3):319–395
Groves NJ, McGrath JJ, Burne TH (2014) Vitamin D as a neurosteroid affecting the developing and adult brain. Ann Rev Nutr 34:117–141
Hansen AL, Olson G, Dahl L, Thornton D, Grung B, Graff IE, Froyland L, Thayer JF (2014) Reduced anxiety in forensic inpatients after a long-term intervention with Atlantic salmon. Nutrients 6(12):5405–5418
Hariri A (2016) Vitamin D deficiency/insufficiency and anxiety among Saudis: degree and differences. Euro Scientific J 12(27)
Hellmuth J, Colby D, Valcour V, Suttichom D, Spudich S, Ananworanich J, Prueksakaew P, Sailasuta N, Allen I, Jagodzinski LL, Slike B, Ochi D, Paul R (2017) Depression and anxiety are common in acute HIV infection and associate with plasma immune activation. AIDS Behav 21(11):3238–3246
Hoang MT, Defina LF, Willis BL, Leonard DS, Weiner MF, Brown ES (2011) Association between low serum 25-hydroxyvitamin D and depression in a large sample of healthy adults: the Cooper Center longitudinal study. Mayo Clin Proc 86(11):1050–1055
Hoffman DL, Dukes EM, Wittchen HU (2008) Human and economic burden of generalized anxiety disorder. Depress Anxiety 25(1):72–90
Holick MF, Chen TC, Lu Z, Sauter E (2007) Vitamin D and skin physiology: a D-lightful story. J Bone Miner Res 22(S2):V28–V33
Hoogendijk WJ, Lips P, Dik MG, Deeg DJ, Beekman AT, Penninx BW (2008) Depression is associated with decreased 25-hydroxyvitamin D and increased parathyroid hormone levels in older adults. Arch Gen Psychiatry 65(5):508–512
Ionescu DF, Niciu MJ, Mathews DC, Richards EM, Zarate CA Jr (2013) Neurobiology of anxious depression: a review. Depressi Anxiety 30(4):374–385
Jorde R, Sneve M, Figenschau Y, Svartberg J, Waterloo K (2008) Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial. J Intern Med 264(6):599–609
Kessler RC, Wang PS (2008) The descriptive epidemiology of commonly occurring mental disorders in the United States. Ann Rev Public Health 29:115–129
Kim Y-K, Jeon SW (2018) Neuroinflammation and the immune-kynurenine pathway in anxiety disorders. Curr Neuropharmacol 16(5):574–582
Kirmayer LJ (2001) Cultural variations in the clinical presentation of depression and anxiety: implications for diagnosis and treatment. J Clin Psychiatry 62:22–30
Lesch KP, Gutknecht L (2005) Pharmacogenetics of the serotonin transporter. Prog Neuro-Psychopharmacol Biol Psychiatry 29(6):1062–1073
Lieb RE, Becker E, Altamura C (2005) The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol 15(4):445–452
Maes M, Verkerk R, Bonaccorso S, Ombelet W, Bosmans E, Scharpé S (2002) Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activation. Life Sci 71(16):1837–1848
Milaneschi Y, Hoogendijk W, Lips P, Heijboer AC, Schoevers R, van Hemert AM, Beekman AT, Smit JH, Penninx BW (2014) The association between low vitamin D and depressive disorders. Mol Psychiatry 19(4):444–451
Murr C, Widner B, Wirleitner B, Fuchs D (2002) Neopterin as a marker for immune system activation. Curr Drug Metab 3(2):175–187
Patrick RP, Ames BN (2014) Vitamin D hormone regulates serotonin synthesis. Part 1: relevance for autism. FASEB J 28(6):2398–2413
Piñeyro G, Blier P (1999) Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol Rev 51(3):533–591
Portman ME, Riskind JH, Rector NA (2012) Generalized anxiety disorder. In: Encyclopedia of human behavior, Second edn. Academic Press, San Diego, pp 215–220
Pu D, Luo J, Wang Y, Ju B, Lv X, Fan P, He L (2018) Prevalence of depression and anxiety in rheumatoid arthritis patients and their associations with serum vitamin D level. Clin Rheumatol 37(1):179–184
Spitzer RL, Kroenker K, Williams JB, Lowe B (2006) A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 166(10):1092–1097
Stahl SM (1998) Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 51(3):215–235
Stone TW (2001) Kynurenines in the CNS: from endogenous obscurity to therapeutic importance. Prog Neurobiol 64(2):185–218
Wittchen H-U, Hoyer J (2001) Generalized anxiety disorder: nature and course. J Clin Psychiatry 62:15–21
The authors are grateful to all patients who participated in the study. The authors also thank the deanship of scientific research (DSR). This work was supported by the deanship of scientific research (DSR)- King Abdulaziz University- Saudi Arabia under Grant [G:209-247-1440].
Conflict of interest
The authors declare that there are no conflicts of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Eid, A., Khoja, S., AlGhamdi, S. et al. Vitamin D supplementation ameliorates severity of generalized anxiety disorder (GAD). Metab Brain Dis 34, 1781–1786 (2019). https://doi.org/10.1007/s11011-019-00486-1
- Vitamin D
- Generalized anxiety disorder